Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DP CD8 TIL KD

Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at tumor cells

Phase 1 Most advanced trial

1 Registered trials

What is DP CD8 TIL KD?

DP CD8 TIL KD is a tumor-infiltrating lymphocyte (TIL) cell therapy administered intravenously. It is being studied in multiple solid tumors including head and neck squamous cell carcinoma, melanoma, gynecologic, colorectal, lung, and urogenital cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Tumor-infiltrating lymphocytes)
Targets: tumor cells (antigen)
Mechanism: Kills target cells, directed at tumor cells
Therapy area: Oncology
In trials of: PHIO
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05902520	Phase 1	HNSCC	Active not recruiting	PHIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerGynecologic CancerHNSCCLung CancerMelanomaUrogenital Cancer

Sources

ClinicalTrials.gov NCT05902520

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z